摘要
目的分析利拉鲁肽联合阿卡波糖对肥胖2型糖尿病患者血糖、血脂水平的影响。方法选取2022年1月至2023年11月宜春市第二人民医院收治的48例肥胖2型糖尿病患者作为研究对象,按照随机数字表法分为对照组与观察组,每组24例。对照组给予阿卡波糖片治疗,观察组在对照组基础上联合利拉鲁肽治疗。比较两组治疗前后血糖指标[空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(postprandial 2 h blood glucose,2 h PBG)、糖化血红蛋白A1c(glycosylated hemoglobin A1c,HbA1c)]、体重指数(body mass index,BMI)、血脂指标[总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、空腹胰岛素(fasting insulin,FINS)]及不良反应发生情况。结果治疗后,两组FBG、2 h PBG、HbA1c水平及BMI均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清TC、TG、LDL-C、FINS水平均低于治疗前,HDL-C水平均高于治疗前,且观察组血清TC、TG、LDL-C、FINS水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病,能有效调节血糖、血脂水平,临床疗效较理想,安全性高,值得临床推广应用。
Objective To analyze the effect of liraglutide combined with acarbose on blood glucose and lipid levels in obese patients with type 2 diabetes mellitus.Methods 48 obese patients with type 2 diabetes mellitus admitted to Yichun Second People's Hospital from January 2022 to November 2023 were selected as the study subjects,and they were divided into the control group and the observation group according to the random number table method,with 24 cases in each group.The control group was treated with acarbose tablet,and the observation group was treated with subcutaneous injection of liraglutide on the basis of the control group.The blood glucose indexes(fasting blood glucose[FBG],postprandial 2 h blood glucose[2 h PBG],glycosylated hemoglobin A1c[HbA1c])and body mass index(BMI),blood lipid indexes(total cholesterol[TC],triglyceride[TG],high-density lipoprotein cholesterol[HDL-C],low density lipoprotein cholesterol[LDL-C],fasting insulin[FINS])and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the levels of FBG,2 h PBG,HbA1c and BMI in the observation group were lower than those before treatment,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05);after treatment,the levels of TC,TG,LDL-C and FINS of the two groups were lower than those before treatment,and the level of HDL-C was higher than that before treatment,and the levels of TC,TG,LDL-C and FINS in the observation group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus can effectively regulate blood glucose and blood lipid levels,the clinical efficacy is ideal and the safety is high,which is worthy of clinical promotion and application.
作者
李玖
傅璘
LI Jiu;FU Lin(Department of Pharmacy,Yichun Second People's Hospital,Yichun,Jiangxi,336000,China)
出处
《当代医学》
2024年第36期123-126,共4页
Contemporary Medicine
基金
宜春市指导性科技计划项目(2022ZDJH6365)。
关键词
利拉鲁肽
阿卡波糖
肥胖
2型糖尿病
血糖
血脂
不良反应
Liraglutide
Acarbose
Obesity
Type 2 diabetes mellitus
Blood glucose
Lipid
Adverse reactions
